Capivasertib Plus Abiraterone in Metastatic Prostate Cancer

16 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Join Dr. Karan Jitwani and Dr. Alan Bryce in this insightful podcast episode as they delve into the latest developments in prostate cancer research, focusing on the CAPItello-280 and CAPItello-281 studies. Dr. Bryce, a leading expert in genitourinary cancers, provides a historical context for these important studies and discusses the implications of the recent CAPItello-281 results presented at ASCO 2026.
In this episode, you'll learn about:
• The role of the androgen receptor in prostate cancer and its parallels with breast cancer treatment strategies
• The significance of the new terminology introduced by the Prostate Cancer Working Group 4, shifting from "castration-resistant" to "androgen pathway modulator-resistant"
• The primary and secondary endpoints of the CAPItello studies, including the implications of positive radiographic progression-free survival (rPFS) results versus disappointing overall survival (OS) outcomes
• The challenges and considerations regarding the toxicity of cabozantinib and its impact on patient quality of life

Website: https://oncupdates.com/
Mail: [email protected]
X/twitter: https://x.com/OncUpdates

Tune in for a comprehensive discussion that sheds light on the evolving landscape of prostate cancer treatment and the critical questions that arise from recent clinical trial results.

#ProstateCancer #CAPItello281 #mCRPC #GUOncology #ClinicalTrials #MedEd
Categoria
Oncology
Commenta per primo questo video.

Prossimo